C2N Diagnostics Partners with Cambridge Cognition and The Alzheimer’s Trust to Improve Alzheimer’s Diagnosis in the UK
C2N Diagnostics and Cambridge Cognition have announced a partnership with The Alzheimer’s Trust, a newly formed subsidiary of The Cancer Screening Trust, to address the growing burden of Alzheimer’s disease and related dementias in the United Kingdom. The collaboration creates an integrated, scalable pathway for earlier and more accurate diagnosis, combining C2N’s MHRA-registered PrecivityAD2 test, Cambridge Cognition’s validated digital touchscreen cognitive assessment platform CANTAB Pathway, and The Alzheimer’s Trust’s national phlebotomy and MRI imaging infrastructure. UK-based healthcare professionals can now order the PrecivityAD2 test and CANTAB Pathway through The Alzheimer’s Trust.
The PrecivityAD2 test uses high-resolution mass spectrometry to measure the ratio of amyloid beta protein isoforms Aβ42 and Aβ40, and the percentage of tau protein phosphorylated at amino acid 217. These values are combined into a proprietary statistical algorithm to calculate the Amyloid Probability Score 2, which provides the likelihood of amyloid plaques in the brain. CANTAB Pathway offers escalating tiers of cognitive assessment tasks designed to provide increasingly greater insight about a patient’s cognition. Research has shown that cognitive performance assessed using CANTAB Pathway is sensitive to blood biomarkers associated with brain amyloid pathology, and that combining digital cognitive assessment with the PrecivityAD2 algorithm detected biomarker-verified Alzheimer’s disease with 90% accuracy across 19 GP clinics in Sweden, compared to standard-of-care accuracy of 70%.
Dementia is the UK’s leading cause of death, claiming more than 76,000 lives each year and affecting an estimated 982,000 people. People in the UK wait an average of 3.5 years from first symptoms to diagnosis, with almost six months spent after a GP referral to a memory clinic, and nearly 75% of GPs acknowledge long waits for diagnosis. These delays have potential clinical consequences, as amyloid-targeting treatments appear most effective when begun in the earliest stages of disease. In 2025, C2N obtained medical device registration from the UK’s MHRA for PrecivityAD2, the first regulatory approval of the test as an in vitro diagnostic anywhere in the world, and the test more recently received FDA clearance in the United States.
Dr. Joel Braunstein, CEO of C2N Diagnostics, said the company is excited to play an important role in this partnership by helping address the dementia diagnosis crisis in the UK, and believes the collaboration could be a model in other parts of the world. Braunstein noted that C2N appreciates what The Cancer Screening Trust has accomplished in oncology and looks forward to similar success with Alzheimer’s disease, and that Cambridge Cognition has been a highly collaborative and trusted partner in educating stakeholders about novel diagnostic tools.
Rob Baker, CEO of Cambridge Cognition, said the dementia diagnostic challenge in the UK demands bold, collaborative action. Baker noted that by uniting C2N’s blood biomarker technology, Cambridge Cognition’s clinically validated digital assessments, and The Alzheimer’s Trust’s commitment to patient-centered care, the partnership offers a new model for how the healthcare system can meet the scale of the crisis.
Dan Hogarty, Director of The Alzheimer’s Trust, said the collaboration with C2N and Cambridge Cognition enables the organization to offer the best tests available to those in need and to address the issue with sensitivity and integrity. Frank Hogarty, CEO of The Alzheimer’s Trust and The Cancer Screening Trust, said The Alzheimer’s Trust can support physician or patient referrals from the whole of the UK and, through its in-house clinical team, support patients through diagnosis and care pathways according to test results, a personalized, patient-centric approach optimized through The Cancer Screening Trust over the last five years.
